Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biocartis closes oversubscribed €55.5mm PIPE

Executive Summary

Biocartis NV raised €55.5mm ($63mm) through an oversubscribed private placement of 5mm new shares at €11.10 apiece (an 8% discount). Funds will support expansion of the Idylla test menu and applications. The fully automated real-time PCR system's menu currently includes tests for melanoma, lung, and colorectal cancers, with assays available for both solid and liquid samples. Proceeds will also go towards sales and marketing activities, manufacturing, and working capital.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies